TrumpRx: How a Government Website Is Destroying PBM Stocks

You walk into your pharmacy. Hand over your discount card.

Walk out paying $149 for a month's supply of Wegovy instead of $1,349.

Sounds too good to be true, right?

That's exactly what TrumpRx.gov is promising.

So, what it is, how it works, and which healthcare companies stand to win or lose under it.

Here's the deal. The White House just launched a website, TrumpRx.gov, that acts like a massive coupon book for prescription drugs. But it's not your grandma's coupon book.

This thing bypasses your insurance completely.

You print a card. Show it at the pharmacy. Pay cash. Done.

The focus? Those crazy-expensive weight-loss drugs everyone's talking about. Ozempic. Wegovy. Zepbound. Drugs that normally cost over a thousand bucks a month.

With TrumpRx? You're looking at $149 to $299 a month.

That's an 85% to 90% discount. Not a typo.

Think of it like this. You know how there's always a middleman taking a cut? In healthcare, those middlemen are called Pharmacy Benefit Managers, PBMs for short.

They negotiate drug prices. They take rebates. They add fees. And somewhere along the way, your $50 drug becomes $500.

TrumpRx cuts them out entirely.

Drug companies like Novo Nordisk $NVO ( ▼ 0.45% ) and Pfizer $PFE ( ▲ 2.03% ) agreed to sell directly to you at "most favored nation" pricing. That's government-speak for "the lowest price we charge anywhere in the world."

Why would they do that? Two reasons.

First, they get to bypass all those PBM fees. Second, they look like heroes. Public relations gold.

But here's where it gets interesting.

Your insurance won't cover this. Can't cover it, actually.

It's cash only. No co-pays. No deductibles. No insurance claims.

For some people, that's perfect. If you're uninsured or your plan doesn't cover weight-loss meds anyway, you just saved a mortgage payment every month.

But if you have good insurance that already covers these drugs? You might be better off sticking with your current plan.

See, once you hit your deductible, insurance usually picks up most of the tab. TrumpRx doesn't help with that.

It's a discount program, not insurance.

Let's talk winners first.

Now for the losers.

No middleman needed? No fees to collect.

$CVS dropped 2% the day TrumpRx launched. That tells you everything.

But will they? History says don't hold your breath.

Other countries might actually pay more. Drug companies have been charging Americans more to subsidize lower prices abroad. If U.S. prices drop to match international rates, companies will need to make up that revenue somewhere.

Critics are already calling it "cost-shifting."

Let's get practical. Should you use TrumpRx?

Use it if:

Skip it if:

Run the numbers. Compare what you'd pay with TrumpRx versus what you'd pay through insurance.

Sometimes the discount program wins. Sometimes your insurance does.

Now, if you're thinking about where to put your money, this gets interesting.

Pharma stocks are mixed. Companies partnering with TrumpRx (Novo Nordisk, Pfizer, Eli Lilly) are seeing volume increases. That's good for revenue.

But gross margins are getting squeezed. Selling drugs for 90% less means less profit per pill. They're making it up in volume, but it's a different business model.

PBM stocks are under pressure. CVS Health, Cigna, UnitedHealth—all down since the announcement. This isn't a one-day blip. It's a structural threat to their business.

Retail pharmacy stocks are up slightly. More prescriptions filled means more revenue, even if the margins are thinner.

The smart money is watching which companies adapt versus which ones fight this trend.

Here's what most people are missing.

This isn't just about cheaper drugs. It's about changing how American healthcare works.

For decades, we've had this opaque system where nobody knows what anything really costs. Your doctor prescribes something. Your insurance "covers" it. You pay a co-pay. Nobody questions it.

TrumpRx is bringing price transparency. You know exactly what you're paying. No surprises. No hidden fees.

Is it perfect? No.

Critics call it a "glorified coupon book" with limited drug selection. They're not wrong. Right now, it's mostly weight-loss drugs and a few common medications.

But it's a start.

If this works, expect it to expand. More drugs. More manufacturers. More savings.

The healthcare industry is watching this closely.

If TrumpRx succeeds, other countries might launch similar programs. Competition could drive prices down even further.

If it fails, it'll be because the middlemen fought back. PBMs have deep pockets and powerful lobbyists. They won't go quietly.

Insurance companies might start their own discount programs to compete. That'd be ironic, insurance companies offering cash discounts that bypass insurance.

But stranger things have happened.

Just don't expect your insurance company to be happy about it.

Do the math. Make the smart choice.

Your wallet will thank you.